<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198146</url>
  </required_header>
  <id_info>
    <org_study_id>9910-34</org_study_id>
    <nct_id>NCT00198146</nct_id>
  </id_info>
  <brief_title>Prevention of Diabetes Progression Trial (PDPT)</brief_title>
  <official_title>PD Initiated/Prevention of Diabetes Progression Trial (PDPT) ZEN119</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pescovitz, Mark D., M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facet Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the efficacy and safety of daclizumab in&#xD;
      preventing the progression of diabetes in children who have just been diagnosed with type I&#xD;
      diabetes. Additional purposes of the study are to investigate the amount of drug in the&#xD;
      children, how quickly it is eliminated from the blood, and analyze the effect of the drug on&#xD;
      the immune reaction to diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">February 23, 2007</completion_date>
  <primary_completion_date type="Actual">February 23, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve, Glucagon Stimulation Testing for c-peptide measurements at 0, +6min and +10min intervals over 2 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirements (units/kg/day)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Newly Diagnosed With Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zenapax</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed type 1 diabetes without previous insulin or oral hypoglycemic therapy.&#xD;
&#xD;
          -  ages 2 to 40 years at diagnosis&#xD;
&#xD;
          -  enroll within 3 months of diagnosis&#xD;
&#xD;
          -  test positive for at least one of the biochemical autoantibodies (ICA-512, GAD 65 or&#xD;
             IAA) prior to enrolling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with an anti-IL-2 directed monoclonal antibody or any other&#xD;
             investigational agent that would interfere with the ability to evaluate the safety and&#xD;
             efficacy of daclizumab.&#xD;
&#xD;
          -  Other immunosuppressive drugs including, but not limited to, corticosteroids,&#xD;
             cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, or azathioprine.&#xD;
&#xD;
          -  Active significant infection&#xD;
&#xD;
          -  Limited life expectancy because of disease other than diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D Pescovitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University - Riley Hospital for Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University - Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daclizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

